The phenomenon of the inhibition of phospholipase C-γ1-dependent signaling pathways, which mediates the epileptogenic consequences of TrkB activation, raises high hopes for the treatment of epilepsy [31]. This evidence concerns the gene NTRK2 and epilepsy.